TY - JOUR
T1 - Quality-of-life after radiotherapy for advanced laryngeal cancer
T2 - Results of a phase III trial of the Dutch Head and Neck Society
AU - Janssens, Geert O.
AU - Langendijk, Johannes A.
AU - Terhaard, Chris H.
AU - Doornaert, Patricia A.
AU - Van Den Ende, Piet
AU - De Jong, Martin A.
AU - Takes, Robert P.
AU - Span, Paul N.
AU - Kaanders, Johannes H.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Background/purpose To report on health-related quality-of-life (HRQoL) of patients with laryngeal cancer, treated in a randomized trial comparing accelerated radiotherapy with carbogen and nicotinamide (ARCON) against accelerated radiotherapy alone (AR). Material/methods HRQoL was assessed using the HRQoL Questionnaire-C30 (QLQ-C30) and the Head & Neck cancer module (QLQ-H&N35) at baseline, at completion of radiotherapy and at 6, 12, and 24 months post-baseline. Results From 269/345 patients (AR: 136/174; ARCON: 133/171) data on HRQoL were available for analysis. Moderate to severe clinical impact of the treatment was observed for nearly all items of the QLQ-C30 and QLQ-H&N35 between baseline and end-of-treatment. At 6 months, scores returned to baseline level with exception of dry mouth, sticky saliva, and taste/smell. No difference between AR and ARCON was observed. At 2 years from baseline, the percentage of patients reporting moderate to severe complaints of dry mouth, sticky saliva, or changes in taste/smell was 30%, 22% and 18%, respectively, while the majority of patients had no or few complaints of swallowing (79%) or speech (64%). Conclusions With accelerated radiotherapy, high local tumor control was obtained while maintaining good speech and swallowing function. Long-term dry mouth, sticky saliva and changes in taste/smell are limited to one quarter of patients. (ClinicalTrials.gov number, NCT00147732).
AB - Background/purpose To report on health-related quality-of-life (HRQoL) of patients with laryngeal cancer, treated in a randomized trial comparing accelerated radiotherapy with carbogen and nicotinamide (ARCON) against accelerated radiotherapy alone (AR). Material/methods HRQoL was assessed using the HRQoL Questionnaire-C30 (QLQ-C30) and the Head & Neck cancer module (QLQ-H&N35) at baseline, at completion of radiotherapy and at 6, 12, and 24 months post-baseline. Results From 269/345 patients (AR: 136/174; ARCON: 133/171) data on HRQoL were available for analysis. Moderate to severe clinical impact of the treatment was observed for nearly all items of the QLQ-C30 and QLQ-H&N35 between baseline and end-of-treatment. At 6 months, scores returned to baseline level with exception of dry mouth, sticky saliva, and taste/smell. No difference between AR and ARCON was observed. At 2 years from baseline, the percentage of patients reporting moderate to severe complaints of dry mouth, sticky saliva, or changes in taste/smell was 30%, 22% and 18%, respectively, while the majority of patients had no or few complaints of swallowing (79%) or speech (64%). Conclusions With accelerated radiotherapy, high local tumor control was obtained while maintaining good speech and swallowing function. Long-term dry mouth, sticky saliva and changes in taste/smell are limited to one quarter of patients. (ClinicalTrials.gov number, NCT00147732).
KW - Accelerated radiotherapy
KW - ARCON
KW - Laryngeal cancer
KW - Quality-of-life
KW - Randomized trial
UR - http://www.scopus.com/inward/record.url?scp=84973650199&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2016.02.023
DO - 10.1016/j.radonc.2016.02.023
M3 - Article
C2 - 27165613
AN - SCOPUS:84973650199
SN - 0167-8140
VL - 119
SP - 213
EP - 220
JO - Radiotherapy & Oncology
JF - Radiotherapy & Oncology
IS - 2
ER -